France Adult Malignant Glioma Therapeutics Market Report 2022 to 2030

France Adult Malignant Glioma Therapeutics Market Analysis

$ 3999

The France Adult Glioma Therapeutics Market is valued at around $61 Mn in 2022 and is projected to reach $111 Mn by 2030, exhibiting a CAGR of 7.9% during the forecast period. The France Adult Malignant Glioma Therapeutics Market is predicted to develop gradually due to glioblastoma's poor prognosis, which drives the need for novel treatments, as well as rising incidence rates that contribute to market expansion. Key players in the France Adult Malignant Glioma Therapeutics Market include companies like Roche, Merck & Co., Novartis, Bayer, Kymab, Cellectis, Lysogene, AbbVie, Bristol-Myers Squibb, and Pfizer among others

ID: IN10FRPH426 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Netal Patel

Buy Now

France Adult Malignant Glioma Therapeutics Market Executive Summary

The France Adult Glioma Therapeutics Market is valued at around $61 Mn in 2022 and is projected to reach $111 Mn by 2030, exhibiting a CAGR of 7.9% during the forecast period.

Malignant glioma in adults is a kind of cancer that starts in the brain and spinal cord, most especially in glial cells, which are the nervous system's supporting cells. The most frequent forms include anaplastic astrocytoma, anaplastic oligodendroglioma, mixed gliomas, and glioblastoma multiforme (GBM), which is the most severe and common kind. GBM is a grade IV tumour that is extremely aggressive and develops quickly. Age, with an increased prevalence in adults, genetic predisposition, radiation exposure, immune system diseases, and hereditary illnesses such as neurofibromatosis are risk factors linked to adult malignant gliomas. Treatment consists of radiation therapy, chemotherapy, and surgery; the prognosis varies according to the kind and grade of the tumour, the treatment objective, and the patient's general health.

The annual age-adjusted incidence of glioblastoma ranges from 0.59 to 3.69 per 100,000 persons, with 64 years being the median age at diagnosis. Glioblastoma makes up 28.2% of all tumours, 35.0% in males and 22.7% in females, and accounts for 62.4% of neuroepithelial tumours. The France Adult Malignant Glioma Therapeutics Market is predicted to develop gradually due to glioblastoma's poor prognosis, which drives the need for novel treatments as well as rising incidence rates that contribute to market expansion.

Key players in the France Adult Malignant glioma Therapeutics Market include companies like Roche, Merck & Co., Novartis, Bayer, Kymab, Cellectis, Lysogene, AbbVie, Bristol-Myers Squibb and Pfizer among others.

Market Dynamics

Market Growth Drivers

The France Adult Malignant Glioma Therapeutics Market is expected to increase progressively in the coming years, owing to many significant factors. Despite available treatments, glioblastoma, the most aggressive glioma subtype, has a terrible prognosis with low long-term survival rates. This unmet medical need generates a substantial demand for innovative and more effective treatments. The rise of personalized medicine, targeted treatments, and immunotherapy offers new pathways for improved glioma management, increasing market growth for these novel therapeutic choices.

Increased investment in research and development, as well as the approval and introduction of novel therapies by industry players, are likely to propel market expansion in France. The steady rise in targeted therapy and monoclonal antibodies has fuelled market growth, providing advanced treatment options for adult malignant gliomas. France already has a rather high glioma incidence compared to other nations, with around 5,500 new cases diagnosed each year. This is likely to remain steady or perhaps ascend with the aging population, as glioma risk increases with age. Growing awareness and enhanced cancer screening as a result of emerging new technologies may lead to earlier diagnosis, hence contributing to therapeutic market growth.

Market Restraints

The France Adult Malignant Glioma Therapeutics Market faces several notable market restraints. For instance, innovative products such as customized medication and immunotherapy are expensive, frequently costing thousands of euros for each treatment term. This can result in uneven access, as certain patients, particularly those without supplemental insurance, may be unable to pay for these expensive procedures. As a result, the economic burden appears to rise, and healthcare systems are under pressure to handle rising expenses linked with expensive glioma therapy.

Another aspect that may act as a barrier to introducing the product to the market is a restriction on clinical trial participation. Because glioma is an uncommon condition, recruiting individuals for clinical trials is difficult. Some people may be hesitant to enrol in studies owing to concerns about adverse effects or the possible benefits. With fewer patients, it takes longer to recruit suitable subjects, limiting research progress.

Healthcare Policies and Regulatory Landscape

France's healthcare system comprises a Statutory Health Insurance (SHI) system that offers universal coverage for its people, as well as a large role for voluntary Supplemental Private Health Insurance (VHI). It is largely supported by employee and employer payments, as well as designated taxes on other revenue streams. The oversight of the French healthcare system is mostly centralized, with the French National Agency for Medicines and Health Products Safety (ANSM) serving as the central administrative enforcement authority for medicines and medical devices. The ANSM is supported in its task by the regional health agencies (ARS), which are responsible for the implementation and enforcement of many regional health policies. It assures the safety of health items such as pharmaceuticals, medical equipment, and cosmetics. The marketing or commercialization of any medicine or medical product in France must be authorized by the ANSM.

Competitive Landscape

Key Players

Roche
Merck
Novartis
Bayer
Kymab
Cellectis
Lysogene
AbbVie
Bristol-Myers Squibb
Pfizer

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Adult Malignant Glioma Therapeutics Market Segmentation

By Disease Type

Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Other Types

By Treatment Type

Chemotherapy
Targeted Drug Therapy
Radiation Therapy
Surgery
Gene Therapy
Immunotherapy
Vaccines

By Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

By Disease Stage

Early-Stage Tumour
Late-Stage Tumour
Palliative Care

By Route of Administration

Oral
Parenteral
Others

By End User

Hospitals
Speciality Clinics
Chemotherapy Centres
Radiotherapy Centres
Homecare
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.